FY22 results were in line with expectations, with cash at period end of $9.8m, giving a cash runway into mid-24. Verici continues to demonstrate strong operational and strategic progress and transitioned from a research only company to a commercial revenue-generating company in January with the launch of its first product Tutivia. Notable progress has been made in securing reimbursement, including the proposed price of $2,650/test being significantly ahead of the assumed rate of $1,500 in our mo ....